You are here:

Archived: stiripentol (DIACOMIT)

Advice

Following a full submission

stiripentol (Diacomit) is not recommended for use within NHS Scotland for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and valproate.

The number of responders with >50% reduction in the number of clonic (or tonic-clonic) seizures was significantly greater in SMEI patients receiving adjunctive stiripentol than in patients receiving placebo.

The product did not gain acceptance by SMC as the manufacturer did not present a formal economic evaluation

Drug Details

Drug Name: stiripentol (DIACOMIT)
SMC Drug ID: 524/08
Manufacturer: BIOCODEX
Indication: In conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 12 January 2009

Current Advice

Resubmission 11 September 2017

Back